Skip to content

Therapeutics

Speeding the time-to-clinic with Optimer®

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…

Oligo therapeutics vs ADCs. How do they stack up?

  Biologics, such as antibody therapeutics have revolutionised our approach to the treatment of disease. Therapeutic antibodies have become the predominant class of drugs in the development pipeline and the…

Aptamer-enhanced gene therapy delivery

Gene therapy is the future for the treatment of several, often life-threatening conditions. Several gene therapy assets are currently under trial targeting cancers, sensory organs, blood disease, and rare…

Aptamers in prostate cancer in vivo research

Prostate cancer is the most common cancer among men, with approximately 1.1 million new cases diagnosed per year worldwide. Most cancer-related deaths are caused by metastases in vital organs,…